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ABSTRACT
The fixed-ratio combination (FRC) of a basal
insulin and a GLP-1 receptor agonist (GLP-1 RA)
has proven to be an effective therapeutic
approach. However, physicians face numerous
practical questions that cannot be answered by
recently published trial results, current guideli-
nes and summaries of product characteristics. In
April 2019, a scientific meeting was held with
the participation of nine experts from four
Central and Eastern European countries to
provide expert consensus on the optimal daily
use of the insulin glargine and lixisenatide FRC
(iGlarLixi). Topics included the positioning and
initiation of iGlarLixi and the management of
treatment. This paper summarizes the outcomes
of the meeting.
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Key Summary Points
The fixed-ratio combination (FRC) of a
basal insulin and a GLP-1 receptor agonist
(GLP-1 RA) has proven to be an effective
therapeutic approach.
Physicians face numerous practical
questions when initiating a fixed-ratio
combination that cannot be answered by
recently published trial results, current
guidelines and summaries of product
characteristics.
A consensus meeting was held with the
participation of experts from four Central
and Eastern European countries to provide
expert consensus on the optimal daily use
of the insulin glargine and lixisenatide
FRC (iGlarLixi).
The experts reached consensus in their
answers to all of the questions presented;
these expert opinions are summarized in
this manuscript.
INTRODUCTION
By the end of the last decade (the 2010s), glu-
cagon-like peptide-1 receptor agonists (GLP-1
RAs) had become important components of
standard care for type 2 diabetes mellitus
(T2DM). Although GLP-1 RAs are valuable in
many aspects for the treatment of diabetes, they
do not seem to stop progressive beta-cell failure,
a key pathophysiology of this chronic
condition. Thus, an appropriate combination of
antidiabetic drugs with different modes of
action is necessary to maintain long-term
metabolic control.
One very promising and particularly effec-
tive therapeutic approach is the fixed-ratio
combination (FRC) of a GLP-1 RA and a basal
insulin. FRCs have only been used in clinical
practice since 2016, so their position in the
diabetes therapeutic algorithm is yet to be fully
established. The latest Position Statement of the
American Diabetes Association and the Euro-
pean Association for the Study of Diabetes
(ADA-EASD Consensus Report [1]) indicates the
therapeutic position of the combination of a
basal insulin and a GLP-1 receptor agonist and
the potential benefits of the FRC over the sep-
arate use of the GLP-1 RA and the basal insulin,
including a decrease in the number of daily
injections required. Currently, two FRCs are
available: insulin degludec/liraglutide (IDe-
gLira) and insulin glargine/lixisenatide
(iGlarLixi).
There is a clear scientific rationale for com-
bining a basal insulin, which mainly reduces
the fasting plasma glucose (FPG) by decreasing
hepatic glucose production and glucagon
secretion but increases body weight, with a
GLP-1 RA, which further improves the FPG but
also reduces postprandial plasma glucose (PPG)
peaks. GLP-1 RAs increase glucose-dependent
insulin secretion, decrease glucagon secretion,
and reduce the gastric emptying rate, food
intake and body weight [2]. The fixed-ratio
coformulation of these drugs has several
advantages compared to basal-bolus insulin
treatment or separate administration of the
components, including a less complex and
more convenient dosing schedule, fewer injec-
tions, easier titration, and lower insulin and
GLP-1 RA doses. In addition, the titration of
FRCs has been shown to improve the gastroin-
testinal tolerability of the GLP-1 RA component
compared to individual administration owing
to slower uptitration than when the GLP-1 RA is
administered alone [2].
The efficacy and safety of the two FRCs
(iGlarLixi and iDegLira) were investigated and
established in the LixiLan and DUAL clinical
development programmes, respectively [2]. The
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DUAL programme, which consisted of nine
randomized clinical trials, confirmed that once-
daily iDegLira generally achieved better gly-
caemic control than basal insulin or liraglutide
alone, was associated with a lower risk of
hypoglycaemic events, and had a more favour-
able patient weight profile than that of basal
insulin alone [2].
The iGlarLixi development programme
encompassed a proof-of-concept phase 2 [3] and
three phase 3 clinical trials (LixiLan-L, -O and -G
[4–6]). In LixiLan-L [4], iGlarLixi achieved lower
HbA1c levels than titrated insulin glargine in
inadequately controlled patients. In LixiLan-O,
which included uncontrolled patients treated
with oral antidiabetic drugs (OADs) [5], iGlarLixi
decreased HbA1c levels more than insulin glar-
gine or lixisenatide alone. The LixiLan-G study
included patients who were inadequately con-
trolled with amaximum tolerated dose of a GLP-
1RA, and thosewho received iGlarLixi achieveda
greater reduction inHbA1c levels than thosewho
continued to use the GLP-1 RA [6]. In all trials,
iGlarLixi was associated with weight loss or
proved to be weight neutral.
A meta-analysis that included studies of both
the DUAL and the LixiLan programmes [7]
showed that FRCs achieved greater reductions
in HbA1c than achieved with various com-
parators (such as placebo or the individual
components of the combination therapies) in
different patient populations who switched
from using a wide range of antidiabetic treat-
ments. Furthermore, FRCs were associated with
weight loss in studies in which patients were
switched from basal insulin to a FRC [7].
The results of the development programmes
and the recently published ADA-EASD Consen-
sus Report provide a solid base of information
for clinicians on how to use FRCs in clinical
practice. However, since routine clinical prac-
tice involves heterogeneous real-life patient
populations, physicians face numerous practical
questions (Table 1) that the above data sources
cannot provide answers to.
Recognizing the significance of these ques-
tions and acknowledging the physicians’ need
for additional information, Sanofi organized an
international expert meeting to discuss these
topics and seek expert consensus on the
practical use of iGlarLixi. For some questions,
the expert opinion was relevant to the thera-
peutic class of FRCs in general. The selection of
participating countries was based on similarities
in routine T2DM clinical practice in the Central
and Eastern European region.
Accordingly, the aims of the expert consen-
sus meeting were as follows:
• To collect experts’ insights regarding practi-
cal questions that arose from the use of
iGlarLixi, and
• To answer those questions in a way that
could be translated into expert consensus
opinions to aid daily clinical practice.
METHODS
Experts from Czech Republic, Hungary, Roma-
nia and Slovakia were invited to discuss these
topics and generate consensual opinions
regarding specific questions. This involved two
main steps:
• First, the experts were asked to validate the
list of the questions initially drafted by
Sanofi. The experts were given the opportu-
nity to modify the questions and supple-
ment the list with additional topics if they
considered that new, clinically relevant
aspects should be discussed. Validation and
insight collection were performed within
individual expert interviews.
• The experts were then invited to a two-day
meeting where the questions were grouped
into three main categories (positioning of
iGlarLixi, treatment initiation of iGlarLixi,
and other questions) and discussed in work-
shops. Discussions in which a consensus was
achieved were summarized in a consensus
document.
After the meeting, the consensus document
was circulated to resolve any disagreements
among the experts. The final version of the
consensus document was approved by each
participating expert. The content of that docu-
ment is summarized in this publication.
The final set of validated and categorized
questions is listed in Table 2.
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The presentation of the expert opinions and
their context, limitations and related informa-
tion follows the structure of the topics and
questions listed above. The opinions are listed
in bullet points in order to aid lucidity and
interpretation.
This article is based on previously conducted
studies, published guidelines and opinions of
leading experts, and does not contain any
studies with human participants or animals
performed by any of the authors.
RESULTS
Positioning of IGlarLixi Versus Other
Treatment Approaches
Sequential Versus Simultaneous Initiation
of Insulin Glargine and Lixisenatide After
OAD Failure
• Should the components of iGlarLixi be ini-
tiated at the same time or sequentially?
The most important factor that should be
considered when choosing iGlarLixi, GLP-1 RA
or basal insulin is the level of HbA1c improve-
ment required to achieve the individualized
glycaemic target. However, there are other
clinical characteristics that should also be taken
into account to decide the most appropriate
method of intensification:
• Comorbidities (with special consideration of
a high/very high risk of CV diseases),
• Risk of hypoglycaemia,
• Level of obesity,
• Significantly increased PPG values (as a root
cause of elevated HbA1c levels), and
• History of gastrointestinal adverse events (GI
AEs) with previous GLP-1 RA treatment.
The experts generally agreed with the cur-
rent ADA-EASD Consensus Report [1] that, after
OAD failure, GLP-1 RA and basal insulin should
be initiated sequentially. However, such an
intensification approach should be imple-
mented in a timely manner and ideally within
the HbA1c range of 7–8%, with a general rec-
ommended HbA1c target of 7%. The single
injectable approach (GLP-1 RA or basal insulin)
might work for a HbA1c range of 8–9% as well;
however, above 9%, HbA1c target achievement
may be compromised, especially if the individ-
ualized HbA1c target is set at \7%. The 9%
HbA1c threshold resonates well with the cur-
rent clinical recommendation of the guideline
to start a FRC if the HbA1c level exceeds the
individual glycated haemoglobin target by 2%
(considering that the HbA1c target of 7% is the
generally recommended HbA1c target in clini-
cal practice).
The following patient characteristics identify
subjects who will potentially benefit more from
iGlarLixi initiation than the separate use of a
GLP-1 RA or basal insulin:
• HbA1c[ 9% (versus any single injection
alone),
• Obesity (versus basal insulin alone),
• High risk for hypoglycaemia (versus basal
insulin alone),
• High PPG levels (versus long-acting GLP-1
RAs or basal insulin), and
Table 1 Important practical questions relating to the use
of fixed-ratio combinations
• Use of GLP-1 RA and basal insulin in combination:
simultaneous (FRC approach) or sequential
initiation?
• Is there a HbA1c threshold beyond which it is not
recommended to start FRCs?
• Can FRCs be used as treatment alternatives for select
patients treated with basal-bolus therapy?
• Can FRCs be used for deintensification?
• Should OADs be continued after starting a FRC? If
not, how should OADs be discontinued?
• Is there an optimal time of the day to use a FRC?
• Should FRCs be considered as intensification options
after GLP-1 RA failure?
•How should the cardiovascular (CV) benefits of GLP-
1 RAs be taken into account when initiating a FRC?
• What should be done when a FRC is no longer
sufficient to provide good glycaemic control?
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• Gastrointestinal adverse events during the
previous GLP-1 RA treatment in the medical
history (versus GLP-1 RA alone).
Choosing Between iGlarLixi and Multiple
Daily Insulin Injection (MDI) in Patients
with a High HbA1c Level After OAD Failure
The most important factor that should be con-
sidered when choosing between iGlarLixi or
MDI is the presence of classic symptoms of
catabolism (i.e. metabolic decompensation). In
the presence of such symptoms, there is no
need for the weight loss effect of GLP-1 RAs;
only the anabolic effects of insulin are needed.
As a consequence, MDI should be the preferred
route for intensifying treatment after OAD
failure.
The experts could not reach a consensus on a
precise HbA1c level which indicates that MDI
should be used if there are no signs of metabolic
decompensation. Nevertheless, measuring fast-
ing C-peptide can help to elucidate whether a
patient with an excessively high HbA1c level
but no catabolic symptoms might benefit more
from MDI than from iGlarLixi.
Furthermore, there are subgroups of patients
with certain clinical characteristics for whom
the practical limitations of MDI should be
considered and iGlarLixi can be a reasonable
treatment alternative:
• Old patients, especially frail subjects and/or
those living alone;
• Patients who are not able to cope with the
burden of multidose adjustment and/or car-
bohydrate counting;
• Patients who cannot self-administer insulin
(i.e. they need external help to administer
insulin) or have a limited adherence to
treatment;
• Patients with poor self-management abilities
or with limited adherence to the frequent
self-monitoring blood glucose tests required
in the setting of a MDI regimen; and
• Patients who cannot afford or are not willing
to conduct multiple daily self-monitoring of
blood glucose (SMBG) tests.
As a conclusion:
Table 2 The final set of questions discussed at the expert
meeting
Category Question
Positioning of iGlarLixi
versus other treatment
approaches
• What is the optimal way
of initiating basal insulin
and a GLP-1 RA in
combination:
simultaneously (i.e.
iGlarLixi) or sequentially
(first GLP-1 RA followed
by basal insulin if
intensification is needed,
or should these be
initiated in the opposite
order)?
• How should we choose
between iGlarLixi and
basal-bolus therapy in
patients with high HbA1c
levels after OAD failure?
• What are the conditions
of and steps involved in
deintensification from
basal-bolus therapy to
iGlarLixi therapy?
Treatment initiation of
iGlarLixi
• What aspects should be
considered when
discontinuing
concomitant OADs
(other than metformin)?
• Is there an optimal time
for the daily
administration of
iGlarLixi?
• How does previous GLP-
1 RA treatment influence
switching to iGlarLixi?
• How should iGlarLixi be
initiated in patients
treated with basal
insulin\ 20 U/day?
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• Sequential initiation of a GLP-1 RA followed
by basal insulin is generally recommended in
patients failing OAD treatment unless the
HbA1c level exceeds 9.0%, in which case a
FRC is more likely to help the patient to
achieve their glycaemic target;
• Both MDI and iGlarLixi can be suitable for
treating patients with a highly elevated
HbA1c level; and
• The main distinction factor should be the
presence of classic catabolic symptoms:
– In the case of catabolic symptoms, MDI is
the regimen of choice (at least for a short
period; subsequent deintensification to a
FRC is an important consideration);
– If a high HbA1c level is not accompanied by
catabolic symptoms, iGlarLixi could be a
reasonable choice for intensification.
Deintensification of the Complex Basal-Bolus
Insulin Regimen with iGlarLixi
• What are the clinical benefits of deintensifi-
cation from basal-bolus therapy to iGlarLixi?
• How can we identify the patients who can be
switched back safely from basal-bolus
treatment?
• What are the practical steps involved in
deintensification? How should this be
achieved in clinical practice?
In general, treatment deintensification or de-
escalation in diabetes care can be defined as
switching to a less-complex alternative antihy-
perglycaemic treatment in order to either
reduce treatment burden (without compromis-
ing efficacy and safety) or target a less ambitious
individualized HbA1c goal due to ageing, the
development of significant comorbidities or the
presence of a high hypoglycaemia risk. In both
cases, FRCs can be considered as treatment
alternatives to the complex basal-bolus insulin
regimen (Table 3).
Patients cannot be excluded from deintensi-
fication based on HbA1c levels or the current
insulin dose alone. However, it should be noted
that the higher the HbA1c level and the higher
the daily insulin dose, the lower the probability
of deintensification success. If these two aspects
are combined (high daily insulin dose and
highly elevated HbA1c levels), the probability of
successful deintensification could be markedly
reduced.
Due to the potential risk of metabolic dete-
rioration, careful planning of patient re-educa-
tion, the setting and the practical algorithm for
deintensification is required.
• Clinical settings in which deintensification
can be carried out include:
– An inpatient setting, which is the preferred
option, especially if the total daily insulin
dose is[0.6 U/kg;
Table 2 continued
Category Question
Other questions • How should the
established CV benefits of
GLP-1 RAs be taken into
account when initiating a
FRC?
• What is the clinical
relevance of PPG when
deciding to choose a
FRC?
• What are the scientific
rationale and practical
steps involved in
intensification in the case
of disease progression in
patients treated with
iGlarLixi?
• How should the
availability of two
injection pens of
iGlarLixi with different
insulin glargine/
lixisenatide ratios be
appraised?
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– An inpatient setting is preferred in Central
and Eastern European countries, but
– The outpatient setting might be an option,
especially if the local healthcare setting does
not allow hospitalization for this treatment
modification, although good patient com-
pliance is essential in this case.
• The mode of deintensification:
– There is currently limited experience on
which to base a firm recommendation for
how a MDI should be discontinued;
– One-step deintensification (discontinu-
ing MDI and initiating iGlarLixi based
on the total daily basal component dose)
could be applied if the previous total
daily insulin dose was B 0.6 U/kg; and
– Gradual discontinuation of basal and/or
bolus insulin might be needed if the
previous total daily insulin dose was[
0.6 U/kg.
Other aspects that should be considered:
• C-peptide measurement is highly recom-
mended to evaluate residual beta-cell func-
tion, which is a prerequisite for safe
deintensification, and the fasting C-peptide
method is preferred;
• Titration of iGlarLixi can usually be per-
formed by patients, but patient education
(e.g. providing an algorithm for titration and
structured SMBG plans) and compliance are
very important in such cases;
• Treatment compliance should be properly
evaluated before deintensification; and
• Detailed analysis of SMBG data by the
physician is needed before and during the
process of deintensification.
In conclusion, the experts highlighted the
need to consider several aspects when choosing
iGlarLixi or a monocomponent of a FRC or MDI
insulin regimen. An important factor is the
presence of classic catabolic symptoms that
require MDI treatment.
In the absence of metabolic decompensa-
tion, the level of HbA1c and the consideration
of different clinical aspects can help to identify
patients who may benefit more from initiating
iGlarLixi than initiating a GLP-1 RA or basal
insulin alone.
Regarding deintensification from MDI, a FRC
treatment can be considered in select patients
in order to reduce treatment burden/complexity
or to decrease the risk of hypoglycaemia or
Table 3 Potential clinical benefits and candidates for
deintensification from the complex basal-bolus insulin
regimen using FRCs
Potential clinical benefits
• Weight loss
• Reduced risk of hypoglycaemia
• Reduced therapy burden
• Better compliance
• Better health-related quality of life
• Lower treatment complexity (e.g. no need for precise
carbohydrate counting), and
• Reduced health resource utilization:
–Reduced need for SMBG
–Fewer emergency room visits due to hypoglycaemic
events, and
–Less consultation with diabetes specialists.
Potential candidates
Patients:
• Who were intensified to MDI due to metabolic
decompensation, acute illness or surgery and then
‘‘left’’ on a MDI;
• For whom the disadvantages of a MDI outweigh the
associated benefits and
–Experienced significant weight gain after basal-bolus
initiation or
–Experienced frequent hypoglycaemic events without
any improvement in glycaemic control;
•Who are not compliant with the MDI and/or SBGM
due to its complexity; and
• Who are well controlled with the MDI but want to
decrease the treatment burden and improve their
health-related quality of life.
Diabetes Ther (2020) 11:1029–1043 1035
weight gain, which are the most frequent
adverse effects of MDI.
Treatment Initiation with iGlarLixi
Discontinuation of Concomitant OADs (Other
Than Metformin)
• Which OADs should be stopped or
continued?
• Should OAD discontinuation be performed
gradually or immediately (in one step at FRC
initiation)? Are there any safety aspects to
consider?
The following aspects should be taken into
consideration when discontinuing OADs:
• Dipeptidyl peptidase-4 (DPP-4) inhibitors
should be stopped, as they have no addi-
tional value to GLP-1 RAs and are not
recommended in association with a GLP-1
RA;
• Sulfonylureas should, as a general rule, be
stopped (to decrease the risk of hypogly-
caemia and weight gain), or the dose should
be substantially reduced;
• Acarbose should be used only rarely and
should be stopped due to the increased risk
of GI side effects;
• Glitazones: a patient-focused decision is key;
if safety concerns about combining it with
insulin (fluid retention, weight gain) exceed
the expected clinical benefit of specifically
targeting insulin resistance, discontinuation
should be considered;
• Sodium/glucose cotransporter 2 (SGLT2)
inhibitors:
– Although the combination of iGlarLixi with
a SGLT2 inhibitor is currently not recom-
mended per the label, the safety profiles and
mechanisms of action of iGlarLixi and
SGLT2 inhibitors do not suggest any addi-
tional safety concerns;
– The combined use of iGlarLixi and a SGLT2
inhibitor is yet to be formally tested in
dedicated clinical trials, but 10% of patients
in the iGlarLixi arm of the LixiLan-G study
[6] continued treatment with a SGLT2
inhibitor after switching to the iGlarLixi
FRC;
– iGlarLixi plus a SGLT2 inhibitor is a poten-
tially beneficial combination due to their
complementary mechanisms of action and
the insulin-independent effect of SGLT2
inhibitors; this combination may be benefi-
cial in most patients;
– A previous clinical trial investigating the
coadministration of SGLT2 inhibitors and
iDegLira seems to support the points men-
tioned above.
Other aspects are as follows:
• When discontinuing OADmedications other
than metformin (see the special considera-
tions for SGLT2 inhibitors discussed above),
they can be discontinued in one step at the
time of iGlarLixi initiation (based on the
results from LixiLan-O).
• iGlarLixi dose titration:
– Titration should be started within a week
after initiation based on fasting SMBG levels
(inappropriate titration may result in meta-
bolic deterioration); and
– The titration algorithm can be individual-
ized (it does not need to be the same as that
used in clinical trials) and should follow the
concept of basal insulin titration.
In conclusion, the Suliqua (Sanofi) SmPC
does not provide additional details on OAD
discontinuation at iGlarLixi initiation, but it
recommends discontinuing all glucose-lowering
drugs except metformin. However, this discon-
tinuation of previous drugs raises questions in
daily practice: to what extent does immediate
discontinuation trigger metabolic instability,
and are there any differences when discontin-
uing different OADs? The experts agreed that
most OAD classes could be stopped as (i) the
approach does not seem to compromise gly-
caemic control and (ii) it may have a potential
safety benefit (continuing OAD in combination
with iGlarLixi may increase the risk of weight
gain, GI side effects, and hypoglycaemic events,
depending on the OAD). The only drugs that
are considered potentially effective and safe to
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combine with iGlarLixi are SGLT2 inhibitors,
but clinical trial data to support this regimen are
currently limited, and it is yet to be included on
the label. Whether the previous OADs were
discontinued gradually or in one step was not
considered to be important by the experts;
however, there was an agreement that the
strong need to start uptitrating iGlarLixi
according to the fasting SMPG immediately
after initiation should be highlighted.
Optimal Time for Daily Administration: Before
Breakfast or Dinner?
• Advantages and disadvantages of breakfast,
lunch and dinner administration
• How a patient’s lifestyle and the pharma-
cokinetics/pharmacodynamics of iGlarLixi
influence the time of administration
The Suliqua SmPC stipulates that iGlarLixi
should be injected within 1 h before a meal, but
it does not specify which meal. The following
aspects should be considered when choosing
the injection time for a specific patient:
• iGlarLixi can be administered with any main
meal according to the patient’s preference;
and
• Once the patient determines the preferred
meal, iGlarLixi should be administered each
day before the chosen meal.
However, there are some clinical considera-
tions that favour one option over the others:
• Before breakfast:
– Postprandial glucose levels are typically
highest after breakfast in most patients;
– Trial evidence from the LixiLan-L and Lix-
iLan-O studies [4, 5] is based on administra-
tion in the morning;
– Lixisenatide serum levels are still relatively
high at the next meal, leading to a relevant
benefit in terms of PPG excursions following
two main meals (for pre-breakfast adminis-
tration, post-breakfast and post-lunch blood
glucose levels can be controlled by lixisen-
atide assuming that there is no more than
4–5 h between the two meals; there is no
such benefit of a pre-dinner injection since
the next main meal (breakfast) is taken
considerably more than 4–5 h after the pre-
dinner injection);
– The risk of nocturnal hypoglycaemia may be
lower with the pre-breakfast injection than
with the pre-dinner injection (due to the PK/
PD characteristics of the basal insulin com-
ponent, insulin glargine); and
– Patients who are uncontrolled on basal-
supported oral therapy and have nocturnal
hypoglycaemia may benefit from a morning
injection.
• Before lunch:
– This is an option when lunch and dinner are
the meals to be covered by lixisenatide
(again, assuming that no more than 4–5 h
elapse between the two meals).
• Before dinner
– This is an option when dinner is the main
meal.
Other aspects are as follows:
– Data from a randomized controlled trial of
lixisenatide [8] demonstrated similar efficacy
and safety profiles for administration in the
morning and evening.
In conclusion, the experts considered that
the patient’s lifestyle and the preferred main
meal were the most important factors when
choosing the timing of the iGlarLixi injection.
It was highlighted that iGlarLixi can cover PPG
elevations after two meals if no more than 4–5 h
elapse between those meals. In addition, data
from a clinical trial indicate that the efficacy
and safety of lixisenatide do not vary depending
on whether it is administered in the morning or
evening. However, morning administration is
supported by several arguments and may pro-
vide the most benefit to patients.
Diabetes Ther (2020) 11:1029–1043 1037
How Does a Medical Treatment History
of GLP-1 RA Use Influence the Switch
to iGlarLixi?
• Should either inadequate efficiency or side
effects be considered a contraindication?
• Are there any causes that imply an absolute
contraindication?
The following aspects should be considered
when the physician decides whether to initiate
iGlarLixi in a patient formerly treated with any
of the GLP-1 RAs:
• iGlarLixi was shown to achieve significantly
better glycaemic control than GLP-1 RAs
alone in patients inadequately controlled by
GLP-1 RA therapy [6];
• The GLP-1 RA class is heterogeneous in terms
of glycaemic control (based on either FPG or
PPG), weight loss and GI side-effect
occurrence;
• If possible, the causes of previous fail-
ure(s) should be clarified to determine
whether they were related to poor tolerabil-
ity (e.g. GI side effects), insufficient patient
compliance or a lack of efficacy; and
• If GI side effects led to GLP-1 RA discontin-
uation or compliance problems in the past,
initiation of iGlarLixi could be considered
based on evidence indicating that it has
better GI tolerability than GLP-1 RA alone
[5, 9].
In conclusion, depending on the rea-
son(s) for the previous GLP-1 RA failure(s),
iGlarLixi can achieve effective glycaemic con-
trol in patients who were uncontrolled with
previous GLP-1 RA therapy. For those who dis-
continued previous GLP-1 RA therapy due to GI
side effects, iGlarLixi treatment with smaller
GLP-1 RA dose increments is likely to be asso-
ciated with a lower risk of such adverse events,
and might therefore result in the successful use
of the GLP-1 RA component.
Treatment Initiation in Patients on Basal
Insulin < 20 U/Day
• Which clinical characteristics should be
considered (risk of hypoglycaemia, levels of
FPG and PPG)?
• What is the recommended starting dose of
iGlarLixi when the prior basal insulin dose
was less than 20 U/day?
For insulin-treated patients, the starting dose
of iGlarLixi is specified in the Suliqua SmPC
and is based on the patients’ preceding daily
basal insulin dose. The lowest insulin dose for
which the iGlarLixi starting dose is specified is
20 U/day, but there is no specified dose for
patients treated with\20 U of basal insulin per
day.
In such a scenario, the following aspects
should be considered:
• In the Central and Eastern European region:
– Few patients with T2DM are treated with a
basal insulin dose of\20 U/day; and
– Insufficient titration of basal insulin is a very
common problem in clinical practice.
• Revision of the current basal insulin therapy
should be performed, taking FPG, PPG and
HbA1c into account.
• If FPG is above the target:
– When there is no concern about hypogly-
caemic events, basal insulin should be upti-
trated and optimized before switching to
iGlarLixi;
– When there is concern about hypoglycaemic
events, switching to iGlarLixi should be
considered instead of increasing the basal
insulin dose, which may further increase the
risk of hypoglycaemia.
• If PPG is uncontrolled and FPG is at the
target (which can be associated with
uncontrolled HbA1c levels as well), initia-
tion of iGlarLixi should be the preferred
choice due to the mode of action of lixisen-
atide, which specifically decreases post-meal
hyperglycaemia.
• In these treatment scenarios, when the cur-
rent daily basal dose is below 20 U, the
starting dose of iGlarLixi should be 10
U/day, similarly to insulin-naı¨ve patients,
due to the better GI tolerance associated
with the lowest applicable dose of the FRC.
After treatment initiation, iGlarLixi can
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potentially be uptitrated with two dose
adjustments per week to achieve sufficient
overall glycaemic control in a timely
manner.
In conclusion, the experts discussed iGlarLixi
initiation in patients treated with less than 20 U
basal insulin/day. They agreed that steps to
optimize glycaemic control in these patients
should be determined by interpreting the levels
of FPG, PPG and HbA1c and the risk of hypo-
glycaemic events. When choosing iGlarLixi to
improve metabolic control, its starting dose
should be the same as that of insulin-naı¨ve
patients (10 U/day).
Other Important Topics
Cardiovascular Benefits of GLP-1 RAs
• How should the established CV benefits of
GLP-1 RAs be taken into account when ini-
tiating a FRC?
Some GLP-1 RAs reduce the risk of CV
events, as has been demonstrated in several
long-term cardiovascular outcome trials [10].
Although the results from these trials do not
necessarily indicate that the CV benefits of GLP-
1 RAs can also be expected when a GLP-1 RA is
administered as a component of a FRC, it is
reasonable to recommend the following based
on the currently available published evidence if
the physician has decided to initiate a FRC:
If a patient has established CV disease:
• iDegLira might be considered the first choice
based on the results of the LEADER trial [11],
although the findings cannot be extrapo-
lated directly to iDegLira, mainly due to the
lower GLP-1 RA doses used when a GLP-1 RA
is applied as a component of a FRC.
If a patient has no established CV disease:
• Glycaemic control and achieving individual
HbA1c target levels are the most important
aspects; and
• Either FRC can be used, mirroring the rec-
ommendation of the current ADA-EASD
consensus.
Additional considerations regarding CV
diseases:
• According to the latest ADA-EASD consensus
statement, approximately 85% of patients
have no established CVD; and
• Some types of CVDs do not always have an
atherosclerotic origin (e.g. heart failure).
As the GLP-1 RA component liraglutide had
a positive effect on MACE when used at a high
dose (whereas lixisenatide had a neutral effect
in ELIXA [12]), iDegLira might be considered
the first-choice FRC for patients with estab-
lished CV disease.
For patients with no established CV disease,
which corresponds to 85% of all patients with
T2DM, there is no preference for either FRC
from the perspective of CV risk.
Measuring PPG and the Concept of ‘‘Residual
Hyperglycaemia’’
It should be noted that PPG is rarely measured
routinely in patients with T2DM in clinical
practice.
• The use of the concept of ‘‘residual hyper-
glycaemia’’ has been suggested when the
level of HbA1c remains suboptimal but the
FPG/fasting SMBG levels are at or close to
target. PPG is most likely to be the factor
behind the elevated HbA1c levels [13]. In
such cases, iGlarLixi has a stronger impact
on postprandial glucose and should be the
first-choice FRC.
• It is recommended that PPG values should be
monitored to facilitate an informed choice
of FRC.
Scientific Rationale and Practical Steps
for Intensification in the Case of Disease
Progression in Patients Treated with iGlarLixi
• What are the patient characteristics that
should be taken into account when selecting
the intensification strategy?
• What are the options to intensify iGlarLixi?
Table 4 summarizes the intensification
strategies that can be used when T2DM pro-
gresses and iGlarLixi no longer provides
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acceptable control (i.e. the HbA1c level is not in
the target range).
In conclusion, the treatment of patients
whose glycaemic status becomes uncontrolled
when they are treated with iGlarLixi should be
intensified in accordance with their FPG and
HbA1c levels and key patient characteristics
such as life expectancy and comorbidities.
Adding a SGLT2 inhibitor, SU or prandial insu-
lin, switching to a MDI regimen, or even setting
higher individual HbA1c target levels and leav-
ing the treatment unchanged are all possible
intensification options.
Appraising the Two iGlarLixi Injection Pens
Available
• What are the beneficial effects and potential
risks of switching between Suliqua pens?
While the availability of two Suliqua pens
with different fixed ratios of the compounds
provides the opportunity to adapt the drug
treatment in a more flexible way, some physi-
cians may feel it increases treatment complex-
ity. The experts were asked to express their
opinions regarding the availability and the
practical use of the two injection pens of
iGlarLixi.
• The availability of two pens with different
compound ratios (1:2 and 1:3) is beneficial
since it allows better treatment individual-
ization to reflect disease status/progression
as follows:
– In the early disease phase (with relatively
well-preserved beta-cell capacity), more GLP-
1 RA is typically required and less insulin is
needed (the 1:2 ratio pen can be used after
OAD failure);
– In the advanced disease phase (with less
residual beta-cell function), more basal insu-
lin (up to 60 U/day) may be needed (the pen
with the 1:3 ratio can be used in this case);
• When patients using basal insulin are initi-
ated with iGlarLixi, the availability of the 1:3
ratio pen ensures that the need to reduce the
applied basal insulin dose is minimized (pa-
tients can even start with 30 U/day depend-
ing on their previous basal insulin dose);
• Mixing up the pens should not warrant
safety concerns, as patients use only one
pen at a particular stage during the course of
the iGlarLixi treatment; and
Table 4 Intensification strategies after the failure of
iGlarLixi
Options for intensifying iGlarLixi if FPG is in the
target range but HbA1c becomes uncontrolled:
• In general, for patients with long life expectancies
(without significant comorbidities):
–A SGLT2 inhibitor can be added (depending on the
estimated glomerular filtration rate);
–A SU (preferably gliclazide MR/glimepiride based on
the ADVANCE and CAROLINA studies [14, 15])
can be added when SGLT2 inhibitors cannot be
prescribed (e.g. due to eGFR, access or cost issues);
and
–Prandial insulin can be added, but MDI is not the
preferred solution
• For patients with significant coexisting medical
conditions or those over 80 years old:
–The individualized HbA1c target level should be re-
evaluated (e.g. relaxed to 8% or even higher) when the
patient is:
• Frail,
• At high risk of hypoglycaemic events, or
• Living alone
–Leaving the treatment regimen unchanged is a
reasonable option for these patients (unless severe
catabolic symptoms are present).
Options for intensifying iGlarLixi if neither FPG nor
HbA1c are in the target range despite reaching 60
U/day basal insulin:
• Switching to the free combination of a GLP-1 RA
and basal insulin and uptitrating basal insulin
• Switching to a full-scale MDI, especially if C peptide
is low.
*All of the above are off-label uses according to the current
SmPC (except for stopping iGlarLixi and switching to the
free combination or full-scale MDI)
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• If needed, it is easy to move from a 1:2 pen to
a 1:3 pen using the same basal insulin dose;
in such cases, the temporary reduction in the
lixisenatide dose (due to the different ratios
of the two compounds) will not have a
clinically relevant impact on glycaemic con-
trol (no deterioration is expected).
In conclusion, the experts considered the
availability of the two Suliqua pens with dif-
ferent fixed ratios to be a clinical advantage
(over iDegLira), making it possible to flexibly
choose between the two ratios according to
patient needs. There were no clinically impor-
tant safety concerns relating to the availability
of the two pens.
CONCLUSIONS
Over the last decade, GLP-1 RAs and fixed-ratio
combinations of them with basal insulin have
become attractive and important options in the
therapeutic armamentarium for people with
T2DM. The recent ADA-EASD Consensus Report
[1] highlighted the advantages of combined
basal insulin and GLP-1 RA therapy over insu-
lin-only regimens. Phase II and III trials [3–6]
provided evidence for the efficacy and safety
[9]) of iGlarLixi FRC when compared to the
individual components of this FRC. Similar
results for iDegLira are also available.
Although the Suliqua SmPC provides
information on how iGlarLixi treatment should
be initiated and titrated in patients with T2DM,
and the results of the clinical trials and post hoc
analyses of them provide evidence on how to
use iGlarLixi, numerous questions have arisen
in daily clinical practice that could not have
been answered by the SmPC and available trial
results. These questions were presented by
Sanofi in a structured format to a group of
leading experts from selected Central and East-
ern European countries (Czech Republic, Hun-
gary, Romania and Slovakia) in a consensus
meeting. The final set of topics and questions
was approved by the experts before the meeting.
The experts reached a consensus for each of
the presented questions. Their expert opinions
may therefore help physicians to use iGlarLixi
in their daily practice.
However, as with any other expert consen-
sus, it should be noted that the recommenda-
tions summarized in this manuscript reflect the
professional opinions of experts, which were
synthesized from their own practical experi-
ences and the limited evidence available at the
time of the expert meeting. With the caveat
that these recommendations are not necessarily
supported by robust evidence from randomized
controlled trials, the authors hope that the
expert opinions reported here will guide physi-
cians on how to best use iGlarLixi in routine
clinical practice.
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